Tag: cellectar biosciences
December 11, 2018
Cellectar Granted Japanese Patent for CLR 131
Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, announces... September 25, 2018
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of... September 17, 2018
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of... August 20, 2018
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of... August 1, 2018
Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate
Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of...
July 29, 2018
5 Top Weekly NASDAQ Biotech Stocks: resTORbio Leads the Pack
resTORbio, ADMA Biologics, Misonix, Novus Therapeutics and Innovate Biopharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index. June 7, 2018